Open AccessArticle
Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022
by
Christoph Friedli, Anke Salmen, Robert Hoepner, Lutz Achtnichts, Sandra Bigi, Tobias Derfuss, Claudio Gobbi, Nicole Kamber, Christian P. Kamm, Jens Kuhle, Patrice Lalive, Stefanie Müller, Athina Papadopoulou, Caroline Pot, Chiara Zecca and Andrew Chan
Cited by 1 | Viewed by 4069
Abstract
Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course. A wide range of disease-modifying drugs are available, which makes the choice of therapy in individual cases considerably
[...] Read more.
Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course. A wide range of disease-modifying drugs are available, which makes the choice of therapy in individual cases considerably more complex. Due to specific regulatory aspects (partly diverging approvals by Swissmedic compared to the European Medicines Agency (EMA), and an independent evaluation process for the Federal Office of Public Health (FOPH) specialities list (SL)), we issued a consensus recommendation regarding specific aspects of immunotherapy for MS in Switzerland in 2019. Here, we present revised recommendations with an update on newly approved drugs and new safety aspects, also in reference to the risk of COVID-19 infection and vaccination.
Full article